Abbott ABT Established Pharmaceuticals — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Abbott's established pharmaceuticals — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Abbott's established pharmaceuticals — R&D?
- Abbott (ABT) reported established pharmaceuticals — R&D of $41M in Q1 2026.
- How has Abbott's established pharmaceuticals — R&D changed year-over-year?
- Abbott's established pharmaceuticals — R&D decreased by 2.4% year-over-year, from $42M to $41M.
- What is the long-term trend for Abbott's established pharmaceuticals — R&D?
- Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — R&D has grown at a -1.8% compound annual growth rate (CAGR), from $186M to $176M.
- What does established pharmaceuticals — R&D mean?
- The amount spent on research and development activities for this specific segment.
- How do you interpret established pharmaceuticals — R&D?
- Higher spending indicates a focus on innovation and future growth, while lower spending may signal a focus on short-term margin preservation.
- How does established pharmaceuticals — R&D compare across companies?
- Standard R&D expense reporting for pharmaceutical business units across the industry.